• Recursion Pharmaceuticals director Blake Borgeson sold 30,000 Class A common shares on Sept. 1, 2026 at $3.34.
• Direct stake fell to 6,158,287 shares following the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001601830-26-000103), on September 02, 2026, and is solely responsible for the information contained therein.